Immutep (IMMP) Liabilities and Shareholders Equity (2011 - 2025)
Immutep's (IMMP) quarterly Liabilities and Shareholders Equity came in at $96.6 million in Q4 2025, down 18.94% YoY from $119.2 million in Q4 2024, and down 3.87% on a QoQ basis from $100.5 million in Q2 2025.
Immutep (IMMP) Liabilities and Shareholders Equity (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $96.6 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 18.94% year-over-year to $96.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $449.3 million (up 4.19% YoY) and the FY2025 annual result came in at $100.5 million, down 24.32% from the prior year.
- Liabilities and Shareholders Equity eased to $96.6 million in Q4 2025, from $100.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $132.8 million in Q2 2024 to a low of $56.5 million in Q4 2022.
- A 5-year average of $90.9 million and a median of $92.1 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 106.83% — and 2022, when it tumbled 35.47%.
- Tracing IMMP's Liabilities and Shareholders Equity over 5 years: stood at $87.6 million in 2021, then sank by 35.47% to $56.5 million in 2022, then soared by 42.6% to $80.6 million in 2023, then soared by 47.96% to $119.2 million in 2024, then decreased by 18.94% to $96.6 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $96.6 million (Q4 2025), $100.5 million (Q2 2025), and $119.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | 96.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 96.65 Mn |
| Jun 30, 2025 | 100.54 Mn |
| Dec 31, 2024 | 119.23 Mn |
| Jun 30, 2024 | 132.85 Mn |
| Dec 31, 2023 | 80.59 Mn |
| Jun 30, 2023 | 98.55 Mn |
| Dec 31, 2022 | 56.51 Mn |
| Jun 30, 2022 | 73.18 Mn |
| Dec 31, 2021 | 87.57 Mn |
| Jun 30, 2021 | 63.17 Mn |
| Dec 31, 2020 | 55.90 Mn |
| Jun 30, 2020 | 30.54 Mn |
| Dec 31, 2019 | 29.35 Mn |
| Jun 30, 2019 | 23.92 Mn |
| Dec 31, 2018 | 34.61 Mn |
| Jun 30, 2018 | 35.58 Mn |
| Jun 30, 2017 | 26.27 Mn |
| Mar 31, 2017 | 26.78 Mn |
| Dec 31, 2016 | 28.63 Mn |
| Jun 30, 2016 | 31.78 Mn |